Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.

ABSTRACT: Glioma is the most common primary brain tumor, characterized by a consistently high patient mortality rate and a dismal prognosis affecting both survival and quality of life. Substantial evidence underscores the vital role of the immune system in eradicating tumors effectively and preventing metastasis, underscoring the importance of cancer immunotherapy which could potentially address the challenges in glioma therapy. Although glioma immunotherapies have shown promise in preclinical and early-phase clinical trials, they face specific limitations and challenges that have hindered their success in further phase III trials. Resistance to therapy has been a major challenge across many experimental approaches, and as of now, no immunotherapies have been approved. In addition, there are several

SUBMITTER: Mishchenko TA 

PROVIDER: S-EPMC10809268 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature